Joyce A. O'Shaughnessy, MD

Articles

Selecting Novel Adjuvant Therapy For Patients With Breast Cancer

May 25th 2022

Following their discussion on the OlympiA and monarchE trials in breast cancer, experts consider when they would use olaparib or abemaciclib in the adjuvant setting.

Adjuvant Abemaciclib in Early Breast Cancer: The monarchE Trial

May 25th 2022

Shared insight on the monarchE trial, which studied adjuvant abemaciclib in patients with HR+, HER2- high-risk early breast cancer.

Adjuvant Olaparib in BRCA-Mutated Breast Cancer: The OlympiA Trial

May 18th 2022

Highlights from the OlympiA trial, which evaluated the use of olaparib in the adjuvant setting in patients with high-risk BRCA-mutated breast cancer.

Breast Cancer: The Evolving Neoadjuvant and Adjuvant Treatment Landscape

May 18th 2022

Joyce O'Shaughnessy, MD, provides a brief overview of novel neoadjuvant and adjuvant treatment approaches being investigated in the setting of breast cancer.

Impact of Molecular Testing on Treatment Options in Breast Cancer

May 11th 2022

Shared insight on specific treatment options in breast cancer made available when patients are found to have actionable targets via molecular testing.

Molecular Testing Platforms in Breast Cancer

May 11th 2022

Expert perspectives on platforms for molecular testing in breast cancer, as well as the actionable targets that treating physicians should be looking for.

ESMO 2021: Updates in Triple Negative Breast Cancer

November 15th 2021

Drs Joyce O’Shaughnessy, Sara Tolaney, Sara Hurvitz, and Mark Pegram examine recent trial data from ESMO 2021 on triple-negative breast cancer.

Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial

November 8th 2021

Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.

Multidisciplinary Care in ILD Management: Role of a Pulmonologist

October 22nd 2021

Shared insight on the benefit of multidisciplinary care and the pulmonologist’s role in identifying and managing interstitial lung disease.

Role of Bronchoscopy in Identifying and Managing ILD

October 15th 2021

Charles A. Powell, MD, MBA, leads a discussion on bronchoscopy’s role in identifying interstitial lung disease.

Optimizing the Management of ILD: Steroids, Therapy Cessation, and Dose Modification

October 15th 2021

A broad review of strategies to manage interstitial lung disease, including steroid use, therapy cessation/rechallenging, and dose reduction.

Managing ILD: Taking Therapeutic Class Into Account

October 8th 2021

Brief considerations for the impact an agent’s therapeutic class can have on how interstitial lung disease should be approached.

Approaching the Management of Interstitial Lung Disease

October 8th 2021

Experts consider the mainstays in ILD management and factors that may dictate one treatment strategy over another.

Dr. O’Shaughnessy on the Utility of Tucatinib in the HER2+ Breast Cancer Brain Metastases

August 18th 2020

Joyce A. O'Shaughnessy, MD, discusses the utility of tucatinib in HER2-positive breast cancer with brain metastases.

Dr. O'Shaughnessy on the Utility of Capivasertib in Targeting Akt in Breast Cancer

March 9th 2020

Joyce A. O'Shaughnessy, MD, discusses the utility of targeting capivasertib in targeting Akt mutations in breast cancer.

Dr. O'Shaughnessy on Role of Chemotherapy in Future TNBC Treatment

March 28th 2017

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, Texas Oncology, and chair of The US Oncology Network, and 2016 Giant of Cancer Care in Community Outreach, discusses the future role of chemotherapy in the treatment landscape of triple-negative breast cancer.

Dr. O'Shaughnessy on Differentiating Between CDK 4/6 Inhibitors

March 11th 2017

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses differentiating between CDK 4/6 inhibitors in breast cancer.

Dr. O'Shaughnessy Discusses New Developments in Molecular Profiling in Breast Cancer

August 27th 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses new developments in molecular profiling in patients with metastatic breast cancer.

Dr. O'Shaughnessy on Using Phosphoprotein Assays to Personalize Treatment for Breast Cancer

August 21st 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses how the results of phosphoprotein assays can impact treatment decisions for select patients with advanced breast cancer.

Dr. O'Shaughnessy on Adding Phosphoprotein Testing to Genomic Testing for Breast Cancer

August 13th 2015

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses insights from adding phosphoprotein testing to genomic testing for patients with breast cancer.